文献速递细菌感染、耐药与抗菌药物

阿普霉素对多重耐药、碳青霉烯耐药及氨基糖苷耐药肠杆菌与鲍曼不动杆菌的体外活性

In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究采用CLSI微量肉汤稀释法检测阿普霉素对来自欧亚非南美的1232株临床分离株的体外活性,并用全基因组测序和工程菌株面板阐明耐药机制。结果显示阿普霉素对大肠埃希菌、肺炎克雷伯菌、肠杆菌属、摩根摩根菌、弗氏柠檬酸杆菌、普罗威登斯菌属、奇异变形杆菌、黏质沙雷菌和鲍曼不动杆菌均有广谱抗菌活性,且对庆大霉素、阿米卡星、妥布霉素和普拉佐米星无交叉耐药。

要点

  • 阿普霉素对多重耐药、碳青霉烯耐药及氨基糖苷耐药的肠杆菌和鲍曼不动杆菌有广谱体外活性。
  • 临床分离株中氨基糖苷修饰酶和rRNA甲基转移酶导致对标准氨基糖苷类耐药,但不影响阿普霉素。
  • 工程菌株面板证实阿普霉素与庆大霉素、阿米卡星、妥布霉素和普拉佐米星无交叉耐药。

核心结论

  • 阿普霉素的广谱抗菌活性优于其他氨基糖苷类,是治疗耐药革兰阴性菌全身感染的有前景候选药物。

研究设计与样本

  • 采用标准CLSI微量肉汤稀释法检测阿普霉素对来自欧洲、亚洲、非洲和南美洲的1232株临床分离株的体外活性。
  • 利用全基因组测序和工程菌株面板(每种菌株携带单一明确耐药机制)提供阿普霉素活性广度的机制依据。

主要发现

  • MIC分布和MIC90值显示阿普霉素对大肠埃希菌、肺炎克雷伯菌、肠杆菌属、摩根摩根菌、弗氏柠檬酸杆菌、普罗威登斯菌属、奇异变形杆菌、黏质沙雷菌和鲍曼不动杆菌均有广谱抗菌活性。
  • 基因型分析显示,多种氨基糖苷修饰酶和rRNA甲基转移酶使相当比例的临床分离株对标准氨基糖苷类耐药,但对阿普霉素不耐药。
  • 工程菌株面板筛选进一步证明阿普霉素与庆大霉素、阿米卡星、妥布霉素和普拉佐米星无交叉耐药。

关键数值与推荐

  • 阿普霉素对上述菌种的MIC90值原文未报告具体数值。
  • 临床分离株对标准氨基糖苷类耐药的比例原文未报告具体数值。

临床怎么用

  • 对于对其他氨基糖苷类耐药的革兰阴性菌感染,阿普霉素可能提供治疗选择,但需进一步临床研究验证。

局限性

  • 本研究仅为体外活性评估,未提供临床疗效或安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Widespread antimicrobial resistance often limits the availability of therapeutic options to only a few last-resort drugs that are themselves challenged by emerging resistance and adverse side effects. Apramycin, an aminoglycoside antibiotic, has a unique chemical structure that evades almost all resistance mechanisms including the RNA methyltransferases frequently encountered in carbapenemase-producing clinical isolates. This study evaluates the in vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii, and provides a rationale for its superior antibacterial activity in the presence of aminoglycoside resistance determinants. METHODS: A thorough antibacterial assessment of apramycin with 1232 clinical isolates from Europe, Asia, Africa and South America was performed by standard CLSI broth microdilution testing. WGS and susceptibility testing with an engineered panel of aminoglycoside resistance-conferring determinants were used to provide a mechanistic rationale for the breadth of apramycin activity. RESULTS: MIC distributions and MIC90 values demonstrated broad antibacterial activity of apramycin against Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Morganella morganii, Citrobacter freundii, Providencia spp., Proteus mirabilis, Serratia marcescens and A. baumannii. Genotypic analysis revealed the variety of aminoglycoside-modifying enzymes and rRNA methyltransferases that rendered a remarkable proportion of clinical isolates resistant to standard-of-care aminoglycosides, but not to apramycin. Screening a panel of engineered strains each with a single well-defined resistance mechanism further demonstrated a lack of cross-resistance to gentamicin, amikacin, tobramycin and plazomicin. CONCLUSIONS: Its superior breadth of activity renders apramycin a promising drug candidate for the treatment of systemic Gram-negative infections that are resistant to treatment with other aminoglycoside antibiotics.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Juhas M, Widlake E, Teo J, et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. J Antimicrob Chemother. 2019. PMID: 30629184. doi:10.1093/jac/dky546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。